An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

BACKGROUND: Immune checkpoint inhibitors (ICIs) demonstrate unprecedented efficacy in multiple malignancies; however, the mechanisms of sensitivity and resistance are poorly understood and predictive biomarkers are scarce. INSPIRE is a phase 2 basket study to evaluate the genomic and immune landscap...

Descripción completa

Detalles Bibliográficos
Autores principales: Clouthier, Derek L., Lien, Scott C., Yang, S. Y. Cindy, Nguyen, Linh T., Manem, Venkata S. K., Gray, Diana, Ryczko, Michael, Razak, Albiruni R. A., Lewin, Jeremy, Lheureux, Stephanie, Colombo, Ilaria, Bedard, Philippe L., Cescon, David, Spreafico, Anna, Butler, Marcus O., Hansen, Aaron R., Jang, Raymond W., Ghai, Sangeet, Weinreb, Ilan, Sotov, Valentin, Gadalla, Ramy, Noamani, Babak, Guo, Mengdi, Elston, Sawako, Giesler, Amanda, Hakgor, Sevan, Jiang, Haiyan, McGaha, Tracy, Brooks, David G., Haibe-Kains, Benjamin, Pugh, Trevor J., Ohashi, Pamela S., Siu, Lillian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417194/
https://www.ncbi.nlm.nih.gov/pubmed/30867072
http://dx.doi.org/10.1186/s40425-019-0541-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417194/
https://www.ncbi.nlm.nih.gov/pubmed/30867072
http://dx.doi.org/10.1186/s40425-019-0541-0

Ejemplares similares